Total preliminary 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively, representing 65% and 66% annual ...

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to ...

44 th Annual J.P. Morgan Healthcare Conference Format: Company presentation Date: Thursday, January 15, 2026 Time: 12:00 PM PT Location: California East at The Westin St. Francis ...

AstraZeneca on Thursday appointed company insider Rick Suarez as the head of its U.S. biopharmaceuticals unit to lead the ...